Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1999 1
2004 3
2005 3
2006 1
2009 1
2010 2
2011 6
2012 1
2013 1
2014 1
2015 1
2016 1
2017 1
2018 3
2019 1
2020 4
2021 9
2022 8
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean s ali[Author] (6 results)?
Inferring gene expression from cell-free DNA fragmentation profiles.
Esfahani MS, Hamilton EG, Mehrmohamadi M, Nabet BY, Alig SK, King DA, Steen CB, Macaulay CW, Schultz A, Nesselbush MC, Soo J, Schroers-Martin JG, Chen B, Binkley MS, Stehr H, Chabon JJ, Sworder BJ, Hui AB, Frank MJ, Moding EJ, Liu CL, Newman AM, Isbell JM, Rudin CM, Li BT, Kurtz DM, Diehn M, Alizadeh AA. Esfahani MS, et al. Among authors: alig sk. Nat Biotechnol. 2022 Apr;40(4):585-597. doi: 10.1038/s41587-022-01222-4. Epub 2022 Mar 31. Nat Biotechnol. 2022. PMID: 35361996 Free PMC article.
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CW, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, Carleton M, Craig AFM, Younes SF, Sahaf B, Sheybani ND, Schroers-Martin JG, Liu CL, Oak JS, Jin MC, Beygi S, Hüttmann A, Hanoun C, Dührsen U, Westin JR, Khodadoust MS, Natkunam Y, Majzner RG, Mackall CL, Diehn M, Miklos DB, Alizadeh AA. Sworder BJ, et al. Among authors: alig sk. Cancer Cell. 2023 Jan 9;41(1):210-225.e5. doi: 10.1016/j.ccell.2022.12.005. Epub 2022 Dec 29. Cancer Cell. 2023. PMID: 36584673 Free PMC article.
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA.
Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, Macaulay CW, Hamilton EG, Chen B, Olsen M, Schroers-Martin JG, Craig AFM, Moding EJ, Esfahani MS, Liu CL, Dührsen U, Hüttmann A, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Kurtz DM, et al. Among authors: alig s. Nat Biotechnol. 2021 Dec;39(12):1537-1547. doi: 10.1038/s41587-021-00981-w. Epub 2021 Jul 22. Nat Biotechnol. 2021. PMID: 34294911 Free PMC article.
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
Lynch RC, Ujjani CS, Poh C, Warren EH, Smith SD, Shadman M, Till B, Raghunathan VM, Alig S, Alizadeh AA, Gulhane A, Chen DL, Tseng Y, Coye H, Shelby M, Ottemiller S, Keo S, Verni K, Du H, Vandermeer J, Gaston A, Rasmussen H, Martin P, Marzbani E, Voutsinas J, Gopal AK. Lynch RC, et al. Among authors: alig s. Blood. 2023 May 25;141(21):2576-2586. doi: 10.1182/blood.2022019254. Blood. 2023. PMID: 36913694 Clinical Trial.
Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, Kühn J, Bleul S, Olsen M, Liu CL, Jin MC, Macaulay CW, Neidert N, Volk T, Eisenblaetter M, Rauer S, Heiland DH, Finke J, Duyster J, Wehrle J, Prinz M, Illerhaus G, Reinacher PC, Schorb E, Diehn M, Alizadeh AA, Scherer F. Mutter JA, et al. Among authors: alig sk. J Clin Oncol. 2023 Mar 20;41(9):1684-1694. doi: 10.1200/JCO.22.00826. Epub 2022 Dec 21. J Clin Oncol. 2023. PMID: 36542815 Free PMC article.
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.
Alig SK, Shahrokh Esfahani M, Garofalo A, Li MY, Rossi C, Flerlage T, Flerlage JE, Adams R, Binkley MS, Shukla N, Jin MC, Olsen M, Telenius A, Mutter JA, Schroers-Martin JG, Sworder BJ, Rai S, King DA, Schultz A, Bögeholz J, Su S, Kathuria KR, Liu CL, Kang X, Strohband MJ, Langfitt D, Pobre-Piza KF, Surman S, Tian F, Spina V, Tousseyn T, Buedts L, Hoppe R, Natkunam Y, Fornecker LM, Castellino SM, Advani R, Rossi D, Lynch R, Ghesquières H, Casasnovas O, Kurtz DM, Marks LJ, Link MP, André M, Vandenberghe P, Steidl C, Diehn M, Alizadeh AA. Alig SK, et al. Nature. 2024 Jan;625(7996):778-787. doi: 10.1038/s41586-023-06903-x. Epub 2023 Dec 11. Nature. 2024. PMID: 38081297
Molecular Monitoring of Lymphomas.
Schroers-Martin JG, Alig S, Garofalo A, Tessoulin B, Sugio T, Alizadeh AA. Schroers-Martin JG, et al. Among authors: alig s. Annu Rev Pathol. 2023 Jan 24;18:149-180. doi: 10.1146/annurev-pathol-050520-044652. Epub 2022 Sep 21. Annu Rev Pathol. 2023. PMID: 36130071 Free article. Review.
Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212).
Stahler A, Hoppe B, Na IK, Keilholz L, Müller L, Karthaus M, Fruehauf S, Graeven U, Fischer von Weikersthal L, Goekkurt E, Kasper S, Kind AJ, Kurreck A, Alig AHS, Held S, Reinacher-Schick A, Heinemann V, Horst D, Jarosch A, Stintzing S, Trarbach T, Modest DP. Stahler A, et al. Among authors: alig ahs. J Clin Oncol. 2023 Jun 1;41(16):2975-2987. doi: 10.1200/JCO.22.02582. Epub 2023 Apr 5. J Clin Oncol. 2023. PMID: 37018649 Clinical Trial.
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Ballhausen A, Karthaus M, Fruehauf S, Graeven U, Müller L, König AO, von Weikersthal LF, Sommerhäuser G, Alig AHS, Goekkurt E, Meyer-Knees JW, Kurreck A, Stahler A, Held S, Kasper S, Heinrich K, Heinemann V, Stintzing S, Trarbach T, Modest DP. Ballhausen A, et al. Among authors: alig ahs. Eur J Cancer. 2023 Sep;190:112955. doi: 10.1016/j.ejca.2023.112955. Epub 2023 Jun 28. Eur J Cancer. 2023. PMID: 37454537 Clinical Trial.
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.
Cherng HJ, Alig SK, Oki Y, Nastoupil LJ, Fayad L, Neelapu SS, Turturro F, Hagemeister F, Craig AFM, Macaulay CW, Rodriguez MA, Lee HJ, McDonnell TJ, Flowers CR, Vega F, Green MR, Feng L, Kurtz DM, Alizadeh AA, Davis RE, Westin JR. Cherng HJ, et al. Among authors: alig sk. Blood Adv. 2023 Apr 11;7(7):1137-1145. doi: 10.1182/bloodadvances.2022008174. Blood Adv. 2023. PMID: 36375046 Free PMC article. Clinical Trial.
54 results